{'Year': '2018', 'Month': 'Jul', 'Day': '15'}
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Germline and tumor pharmacogenomics impact drug responses, but germline markers less commonly guide oncology prescribing. The authors hypothesized that a critical number of clinically actionable germline pharmacogenomic associations exist, representing clinical implementation opportunities.